Bringing personalized medicine to the forefront of treatment for patients with brain and spinal tumors is of specific interest to Dr. Chetan Bettegowda. His research is dedicated to developing targeted therapies for patients with primary and metastatic tumors of the brain and spine. As part of this research, he has helped identify key genetic pathways that are altered in brain tumors, and he is developing clinical trials to selectively target these pathways. Dr. Bettegowda is also spearheading an ongoing clinical protocol to develop a simple blood test that can detect and monitor disease burden in patients with tumors affecting the central nervous system
Clinical Trial Keywords
Ongoing clinical protocol to develop a simple blood test that can detect and monitor disease burden in patients with tumors affecting the central nervous system
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma. IRB Number: IRB00079861.
This study plans to test overall survival in patients treated with the medication Toca 511 (vocimagene amiretrorepvec), combined with Toca FC (flucytosine) tablets. This combination medication is being used to test to see if it works well for treating high grade gliomas patients whom have suffered a recurrence of their tumor.